Selective HDAC3 inhibitors

Patent metadata

Field	Value
Publication number	US-9139583-B2
Application number	US-201414169775-A
Country	US
Kind code	B2
Filing date	Jan 31, 2014
Priority date	Feb 1, 2013
Publication date	Sep 22, 2015
Grant date	Sep 22, 2015

Abstract

Provided herein are inhibitors of HDAC3, as well as methods of treatment comprising administering those compounds to a subject in need thereof.

First claim

We claim:

1. A compound selected from the following:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

3. A method of treating type 2 diabetes, Huntington's disease, spinal and bulbar muscular atrophy, or lung cancer in a subject comprising administering to the subject a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the disease is type 2 diabetes.

5. The method of claim 3 , wherein the disease is Huntington's disease.

6. The method of claim 3 , wherein the disease is spinal and bulbar muscular atrophy.

7. The method of claim 3 wherein the disease is lung cancer.

8. The method of claim 3 , wherein the subject is human.

9. A compound which is:

or a pharmaceutically acceptable salt thereof.

10. A compound which is:

or a pharmaceutically acceptable salt thereof.

11. A compound which is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Acetylon Pharmaceuticals Inc

Inventors

• Van Duzer John H
• Mazitschek Ralph

Classifications

• C07D235/06

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2 · CPC title

• C07D209/34

  in position 2 · CPC title

• C07D231/56

  Benzopyrazoles; Hydrogenated benzopyrazoles · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D215/54

  attached in position 3 · CPC title